

# Partnering in Cardiometabolic Diseases



Our goal is to discover and develop breakthroughs in animal health for diseases with significant unmet need. To achieve this, we're investing in cutting-edge science and technology to expand and accelerate our drug discovery for the next generation of treatments and preventive therapies. Our track record of innovation excellence in cardiometabolic diseases includes treatments for hypertension in cats, congestive heart failure in dogs and the prevention of heartworm disease in dogs. In addition, we continue to pursue first-in-class innovation across a range of cardiometabolic diseases where limited or no treatment options exist.

Collaborations with innovative and entrepreneurial partners are helping solve the biggest challenges in animal health. We believe that by working together we can bring critical diversity to innovation and accelerate the next wave of therapeutics that will transform the health and well-being of animals now and in generations to come.

## Partnering Interests

Actively pursuing new partnerships in our research focus areas and open to a variety of partnership models to explore:

- Disease-modifying or palliative assets with novel modes of action
- Biomarkers/diagnostic tools enabling early disease detection and/or facilitating demonstration of treatment efficacy
- Novel models to establish efficacy for dogs or cats

## Research Focus

- Canine mitral valve disease
- Cardiomyopathies
- Chronic kidney disease
- Fibrosis
- Diabetes

SCAN ME



## Investing in Animal Health Innovation



**450+ million EUR**

R&D for new medicines



**Global**

R&D presence in Europe, N. America, Asia



**~1,200**

staff in R&D facilities worldwide



**>250**

innovation collaborations

## Some of our Products

**vet<sup>o</sup>edin**  
(pimobendan) CHEWABLE TABLETS

**Heartgard<sup>o</sup> Plus**  
(ivermectin/pyrantel)

**Semintra<sup>o</sup>**  
(telmisartan oral solution)

## Collaboration Driving Innovation

- Growing our global community of innovation partners
- Multiple collaborations advancing new therapies
- Long-term partnerships for the next generation of breakthroughs

## Meet the Team



**Kate Christmas**

[kathryn.christmas@boehringer-ingelheim.com](mailto:kathryn.christmas@boehringer-ingelheim.com)

